Ustyugova, Anastasia
Boehringer Ingelheim (Germany)
3 papers on CoChat
Most cited papers
- Verified
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal
Heart Failure Treatment and ManagementDiabetes Treatment and Management
Cited by 217
- Verified
Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial
Reifsnider, O. S., Kansal, A. R., Wanner, C., Pfarr, E., Koitka-Weber, A., Brand, S. B., Stargardter, M., Wang, C., Kuti, E., & Ustyugova, A. (2022) · American Journal of Kidney Diseases
Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management
Cited by 52
- Verified
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis
Venous Thromboembolism Diagnosis and ManagementHealth Systems, Economic Evaluations, Quality of Life
Cited by 11
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free